Purple Biotech (NASDAQ:PPBT – Get Free Report) and Equillium (NASDAQ:EQ – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.
Insider & Institutional Ownership
9.6% of Purple Biotech shares are held by institutional investors. Comparatively, 27.1% of Equillium shares are held by institutional investors. 3.0% of Purple Biotech shares are held by company insiders. Comparatively, 17.8% of Equillium shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Purple Biotech and Equillium’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Purple Biotech | N/A | -98.44% | -83.37% |
| Equillium | N/A | -88.50% | -72.55% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Purple Biotech | N/A | N/A | -$26.39 million | ($20.45) | -0.18 |
| Equillium | $41.10 million | 3.98 | -$22.40 million | ($0.32) | -8.09 |
Equillium has higher revenue and earnings than Purple Biotech. Equillium is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Purple Biotech has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Equillium has a beta of 1.67, indicating that its share price is 67% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings for Purple Biotech and Equillium, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Purple Biotech | 1 | 1 | 1 | 0 | 2.00 |
| Equillium | 1 | 1 | 5 | 1 | 2.75 |
Purple Biotech currently has a consensus price target of $30.00, suggesting a potential upside of 713.01%. Equillium has a consensus price target of $7.67, suggesting a potential upside of 196.01%. Given Purple Biotech’s higher probable upside, equities analysts plainly believe Purple Biotech is more favorable than Equillium.
Summary
Equillium beats Purple Biotech on 11 of the 13 factors compared between the two stocks.
About Purple Biotech
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
About Equillium
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Receive News & Ratings for Purple Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Purple Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
